Aurinia Pharmaceuticals (AUPH) shares were up more than 10% in recent trading Thursday after the company reported better-than-expected Q3 net income and revenue.
The company reported Q3 net income Thursday of $0.10 per diluted share, swinging from a net loss of $0.09 per share a year earlier.
Analysts polled by Capital IQ expected earnings of $0.02 per share.
Net revenue for the quarter ended Sept. 30 was $67.8 million, compared with $54.5 million a year earlier.
Analysts polled by Capital IQ expected $57.7 million.
The company said it will implement strategic restructuring, which includes reducing its workforce by about 45%, to focus on the commercial strategy for its Lupkynis treatment for lupus nephritis. This restructuring is estimated to yield over $40 million in annualized savings and $15 million to $19 million one-time charge in Q4.
Price: 8.33, Change: +0.81, Percent Change: +10.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。